-
SWI/SNF Complex Related Products (91)
Related Products (91)
-
SGC-BRDVIII-NC
0 ImagesCat. No.: HY-176822CAS No.: 2650530-02-0SGC-BRDVIII-NC (Compound 35) is a negative control compound of SMARCA2/4 and PB1 bromodomain (BRD) inhibitor. SGC-BRDVIII-NC completely abolishes protein-ligand binding capacity with the methylation of the phenolic hydroxyl moiety. SGC-BRDVIII-NC can be used for adipogenesis research.
-
PROTAC SMARCA2/4 degrader-20
0 ImagesCat. No.: HY-163873CAS No.: 2568277-38-1
-
PROTAC SMARCA2/4 degrader-15
0 ImagesCat. No.: HY-163868CAS No.: 2568276-81-1
-
BRM/BRG1 ATP-IN-8
0 ImagesCat. No.: HY-178490CAS No.: 2468046-72-0BRM/BRG1 ATP-IN-8 (Compound Cpd14) is an orally active BRG1/BRM ATPase domain inhibitor. BRM/BRG1 ATP-IN-8 exerts antitumor effects by disrupting aberrant chromatin remodeling in cancer cells, inducing apoptosis and growth arrest. BRM/BRG1 ATP-IN-8 is promising for research of BRG1/BRM-dependent malignancies, including hematological cancers, prostate cancer, breast cancer, and Ewing's sarcoma.
-
(R)-SR-C-107
0 ImagesCat. No.: HY-169937(R)-SR-C-107 is an orally available inhibitor of ENL (YEAST domain-containing protein) designed to target acute myeloid leukemia (AML). (R)-SR-C-107 targets ENL with IC50 and KD of 40 nM and 144 nM, respectively. (R)-SR-C-107 demonstrates in vivo efficacy in a xenograft mouse model of AML, with a tumor regression rate of 45% at a dose of 200 mg/kg (PO; QD).
-
PROTAC SMARCA2/4 degrader-4
0 ImagesCat. No.: HY-159455CAS No.: 2568523-81-7PROTAC SMARCA2/4-degrader-4 (Compound I-434) is a PROTAC degrader for catalytic subunit of the SWI/SNF complex SMARCA2 and SMARCA4. PROTAC SMARCA2/4-degrader-4 degrades SMARCA2 in MV411 and in A549 with DC50 <100 nM, degrades SMARCA4 in MV411 with DC50 <100 nM. (Pink: Ligand for target protein (HY-159472); Black: Linker (HY-159478); Blue: Ligand for E3 ligase (S,R,S)-AHPC (HY-125845))
-
BRG1-IN-1
0 ImagesCat. No.: HY-144720CAS No.: 2616813-99-9BRG1-IN-1 (Compound 11d) is a potent inhibitor of SMARCA4/BRG1. BRG1-IN-1 shows better efficacy than PFI-3 in sensitizing GBM cells to the antiproliferative and cell death inducing effects of Temozolomide in vitro. BRG1-IN-1 enhances the inhibitor effect of Temozolomide on the growth of subcutaneous GBM tumors.
-
PROTAC SMARCA2/4 degrader-5
0 ImagesCat. No.: HY-159456CAS No.: 2568277-84-7
-
SMARCA2 ligand-8
0 ImagesCat. No.: HY-W874018CAS No.: 2933254-33-0
-
C620-0696
0 ImagesCat. No.: HY-115663CAS No.: 902156-98-3C620-0696 is an inhibitor targeting the brom domain of BPTF, with a KD value of 35.5 μM. C620-0696 can exert cytotoxic effects on A549 and H358 cells, inhibiting the expression of c-Myc. C620-0696 inhibits cell migration and colony formation, and induces apoptosis and cell cycle arrest. C620-0696 can be used in the research of non-small cell lung cancer.
-
SMARCA2-IN-4
0 ImagesCat. No.: HY-122645CAS No.: 1915012-19-9SMARCA2-IN-4 (Compound 26) is an inhibitor for SWI/SNF chromatin remodeling complexe SMARCA by targeting the bromodomains. SMARCA2-IN-4 exhibits high affinity for PB1(5), SMARCA2B and SMARCA4 with Kd of 124, 262 and 417 nM.
